Is Allergy Therapeutics plc (AGYTF) a Buy, Sell, or Hold?
OTC : AGYTF
Allergy Therapeutics plc — News
$0.15 USD
$0 (0.0%)
- Volume
- 7.14K
- Average Volume
- 625
- Market Capitalization
- $756.3M
- P/E Ratio
- -5.96
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.15
- Year Low
- $0.09
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.13
| Source | Headline |
|---|---|
|
FTSE 100 Live: London stocks surge, Wall St volatile as SpaceX trading nears
FTSE 100 jumps 162 points to 10,466 Brent crude futures fall then rise UK economy contracts 0.1% in April Housebuilders show strong recovery 4.17pm:... proactiveinvestors.com - 2026-06-12 12:18:00 |
|
Allergy Therapeutics to showcase pollen and food allergy progress
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) said it will use Europe's flagship allergy and clinical immunology congress to showcase progress across its pollen and food allergy pipeline, including clinical proof-of-concept data for its VLP Peanut candidate. The AIM-listed biotechnology company will present 15 posters and oral presentations at the European Academy of Allergy and Clinical Immunology Congress 2026, which takes place in Istanbul, Türkiye, from 12 to 15 June. proactiveinvestors.co.uk - 2026-06-12 04:15:52 |
|
Allergy Therapeutics to showcase pollen and food allergy progress
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) said it will use Europe’s flagship allergy and clinical immunology congress to showcase progress... proactiveinvestors.com - 2026-06-12 04:04:00 |
